CSIMarket
 
Integrated Biopharma Inc  (INBP)
Other Ticker:  
 
 
Price: $0.3100 $-0.01 -1.587%
Day's High: $0.3487 Week Perf: -20.51 %
Day's Low: $ 0.30 30 Day Perf: -8.93 %
Volume (M): 17 52 Wk High: $ 0.42
Volume (M$): $ 5 52 Wk Avg: $0.28
Open: $0.34 52 Wk Low: $0.16



 Market Capitalization (Millions $) 10
 Shares Outstanding (Millions) 31
 Employees 50
 Revenues (TTM) (Millions $) 50
 Net Income (TTM) (Millions $) 0
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 1

Integrated Biopharma Inc
Integrated Biopharma Inc. is a publicly traded company based in the United States that operates in the biopharmaceutical industry. The company focuses on research, development, and production of specialty ingredients and raw materials for the health and nutritional industry. Integrated Biopharma specializes in the production of botanical extracts, dietary supplements, vitamins, and other natural health products. The company is committed to high quality and sustainable practices in its production processes. With a strong customer base, Integrated Biopharma Inc. aims to provide innovative and effective solutions to support the health and well-being of individuals worldwide.


   Company Address: 225 Long Ave. Hillside 7205 NJ
   Company Phone Number: 319-6962   Stock Exchange / Ticker: INBP


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV        1.43% 
BMY   -1.46%    
JNJ        1.4% 
LLY   -0.52%    
MRK   -2.46%    
PFE   -1.17%    
• View Complete Report
   



Integrated Biopharma Inc

Integrated Biopharma Inc. Reports Steady EPS Amid Financial Period

Integrated Biopharma Inc, a leading biopharmaceutical company, has recently released its financial results for the January to March 31, 2024 financial period. These results indicate several significant changes and improvements compared to the previous year.
Firstly, the income per share for INBP remained unchanged at $0.01 per share, in contrast to the previous year where it was $0.00 per share. This shows stability and consistency in the company's earnings. Moreover, the income per share turned positive from a negative value of $-0.01 per share from the preceding reporting season. This demonstrates a positive shift in profitability for Integrated Biopharma Inc.

Integrated Biopharma Inc

Integrated Biopharma Inc Faces Alarming Decline in Q2 2024 Revenue

Integrated Biopharma Inc is a pharmaceutical company that operates in the Major Pharmaceutical Preparations industry. In the most recent fiscal period, the company experienced a loss of $0.01 per share, compared to a profit of $0.03 per share the previous year and break-even results in the preceding financial reporting period. This decline in profitability is concerning for investors as it indicates a downward trend in the company's financial performance.
One of the main reasons for the decline in profitability is the substantial decrease in revenue. Compared to the same period last year, revenue decreased by 14.15% to $10.52 million, and sequentially, revenue fell by 18.017% from $12.83 million. This drop in revenue is significant, especially when compared to the rest of the Major Pharmaceutical Preparations industry, which recorded a top-line improvement during the same period. This suggests that Integrated Biopharma Inc is not keeping up with its competitors, potentially due to various market factors or internal issues within the company.

Integrated Biopharma Inc

Integrated Biopharma Inc Achieves Promising 4.105% Growth in Q3 FY 2023

During the past week, Integrated Biopharma Inc (IBI) experienced a slight increase in its shares by 1.12%. This brings the year-to-date performance for IBI to a significant decrease of -23.27%. Currently, IBI shares are trading at a significant discount of -22.5% below its 52-week average.
In terms of financial performance, IBI reported its most recent fiscal period with zero earnings per share (EPS), compared to the same period the previous year. This is also consistent with the preceding quarter. However, despite the lack of earnings, IBI's revenue saw a slight increase of 4.105% to $12.83 million, compared to $12.33 million in the same quarter a year ago. Sequentially, the company's revenue increased by 3.626% from $12.38 million.

Integrated Biopharma Inc

INBPsn Unveil Latest Financial Results



Integrated Biopharma Inc recently released its financial results for the fiscal period ending June 30, 2023. The report highlights a decrease in revenue, net earnings, as well as a decline in operating and net margins. Additionally, the company's stockpiles remain below the previous year's level. This article aims to outline the key facts from the financial results and provide an analysis of Integrated Biopharma Inc's performance.
Financial Results Overview:
1. Earnings per Share (EPS): In the fiscal period ending June 30, 2023, Integrated Biopharma Inc recorded an EPS of $0.00 per share, compared to $0.05 per share in the same period a year ago. This figure also remained consistent with the preceding reporting period.

Integrated Biopharma Inc

Integrated Biopharma Inc's Revenue Plummeted by -16.221% in Q3 2023: A Detailed Analysis

Integrated Biopharma Inc's Fiscal Third Quarter of 2023: Insights and Analysis
Integrated Biopharma Inc, a healthcare company operating in the United States, has recently released its financial results for the fiscal third quarter of 2023. In this article, we will delve into the details of the report and provide insights and analysis into the company's performance.
The report shows that Integrated Biopharma Inc reached zero gain of $0.00 per share for the fiscal third quarter of 2023, in comparison to $0.03 per share in the same quarter a year earlier and in the preceding quarter. Correspondingly, revenue declined by -16.221% to $13.10 million from $15.63 million in the same quarter a year earlier, but increased sequentially by 6.888% from $12.25 million. Net profits of $0.016 million in the fiscal third quarter of 2023 dropped by -97.99% from zero gain in the corresponding period a year before.







Integrated Biopharma Inc's Segments
Europe    16.34 % of total Revenue
Contract Manufacturing    97.02 % of total Revenue
Other Nutraceutical Business    4.82 % of total Revenue
UNITED STATES    85.5 % of total Revenue
UNITED STATES Contract Manufacturing    80.68 % of total Revenue
UNITED STATES Other Nutraceutical Business    4.82 % of total Revenue
Non-US    16.34 % of total Revenue
Non-US Contract Manufacturing    16.34 % of total Revenue





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com